All In Biotech

Drug Trial Radar · NCT06392386

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Jun 28, 2024

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Apr 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric participants with gMG aged 2 to \<18 years. The primary goal is to confirm an appropriate dose of efgartigimod PH20 SC for pediatric patients using PK and PD results from this study. Participants will receive injections of efgartigimod PH20 SC and will be monitored for safety until the end of the study. At the end of the follow-up period, eligible participants may roll over to an open-label extension (OLE) study. The participants will be in the study for up to 14 weeks.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • Efgartigimod PH20 SCBiological

    Subcutaneous injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efgartigimod serum concentrations as input for compartmental, model-driven analysis to determine age and size dependency of Clearance (CL)Time frame: Up to 12 weeks
  2. Efgartigimod serum concentrations as input for compartmental, model-driven analysis to determine age and size dependency of Volume Distribution (Vd)Time frame: Up to 12 weeks
  3. Total G immunoglobulins (IgG) levels as input for pharmacokinetics (PK)/pharmacodynamics (PD) modelling analysisTime frame: Up to 12 weeks
  4. Anti-acetylcholine receptors antibodies (AChR-Ab) as input for pharmacokinetics (PK)/ pharmacodynamics (PD) modelling analysisTime frame: Up to 12 weeks

Locations

22 sites in 14 countries. Site status is shown where the registry gives one.

  • Carolinas HealthCare System Neurosciences Institute - Neurology

    Charlotte, North Carolina · Active not recruiting

  • Neurology Rare Disease Center

    Denton, Texas · Active not recruiting

  • University of Virginia

    Charlottesville, Virginia · Active not recruiting

  • Sydney Children's Hospital

    Randwick, Australia · Recruiting

  • Royal Children's Hospital Melbourne

    Melbourne, New South Wales, Australia · Recruiting

  • UZ Gent

    Ghent, Belgium · Recruiting

  • Childrens Hospital of Eastern Ontario

    Ottawa, Canada · Recruiting

  • Fakultni nemocnice Brno

    Brno, Czechia · Recruiting

  • Fakultni nemocnice Ostrava

    Ostrava, Czechia · Recruiting

  • AP-HM- Hôpital de La Timone

    Marseille, France · Recruiting

  • Universitätsklinikum Essen

    Essen, Germany · Recruiting

  • Hadassah Medical Center- Ein Kerem

    Jerusalem, Israel · Recruiting

  • Schneider Children's Medical Center of Israel

    Petah Tikvah, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center Ichilov

    Tel Aviv, Israel · Recruiting

  • Istituto G Gaslini Ospedale Pediatrico IRCCS

    Genova, Italy · Recruiting

  • Leiden University Medical Center

    Leiden, Netherlands · Recruiting

  • Uniwersyteckie Centrum Kliniczne w Gdansku

    Gdansk, Poland · Recruiting

  • Neurologia Śląska Centrum Medyczne

    Katowice, Poland · Recruiting

  • Centralny Szpital Kliniczny - Uniwersyteckie Centrum Kliniczne WUM

    Warsaw, Poland · Recruiting

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, Spain · Recruiting

  • Hôpital Nestlé

    Lausanne, Switzerland · Recruiting

  • Oxford Children's Hospital

    Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.